Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.49 |
| ▸ | PDE4A | P27815 | 8/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PDE1A | P54750 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15981495 | 0.87 | CA1 (0.54) | CA1CA2PDE3AROCK2ROCK1 | |
| SCHEMBL12475507 | 0.86 | ROCK2 (0.64) | CA1CA2ROCK2ROCK1KLK5 | |
| Hydrochloric Acid SCHEMBL29456239 | 0.85 | ROCK2 (0.62) | CA1CA2ROCK2ROCK1KLK5 | |
| Hydrochloric Acid SCHEMBL19838204 | 0.85 | ROCK2 (0.62) | CA1CA2ROCK2ROCK1KLK5 | |
| SCHEMBL500368 | 0.84 | CA1 (0.59) | CA1CA2PDE3AKLK5PDE4B | |
| SCHEMBL5583511 | 0.84 | CA1 (0.59) | CA1CA2PDE3AKLK5PDE4B | |
| SCHEMBL2529581 | 0.84 | PDE4B (0.70) | PDE3AROCK2ROCK1KLK5PDE4B | |
| SCHEMBL19605204 | 0.83 | CA1 (0.57) | CA1CA2PDE3AKLK5PDE4B | |
| SCHEMBL14363857 | 0.83 | CA1 (0.57) | CA1CA2PDE3AKLK5PDE4B | |
| Hydrochloric Acid SCHEMBL2530428 | 0.82 | PDE4B (0.68) | PDE3AROCK2ROCK1KLK5PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500569-B1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| EP-3500569-B1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| CN-109641892-B | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | 默克专利有限公司 | 2021-07-02 | — | — | CN | disclosed |
| WO-2020131573-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | NUREDIS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| EP-3500569-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| EP-3204382-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| EP-2673281-B1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-8933018-B2 | Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933018-B2 | Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2673281-A1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012109164-A1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | BTK, SYK, LCK | CA1 4833/4885CA2 1990/4885PDE3A 1038/4885 |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | CA1 4868/4885CA2 3557/4885PDE3A 1610/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | CA1 4882/4885CA2 4062/4885PDE3A 1443/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | CA1 4868/4885CA2 3557/4885PDE3A 1610/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | CA1 2152/4885CA2 3650/4885PDE3A 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.